Entz-Werlé Natacha, Marcellin Luc, Gaub Marie-Pierre, Guerin Eric, Schneider Anne, Berard-Marec Perrine, Kalifa Chantal, Brugiere Laurence, Pacquement Helène, Schmitt Claudine, Tabone Marie-Dominique, Jeanne-Pasquier Corinne, Terrier Philippe, Dijoud Frédérique, Oudet Pierre, Lutz Patrick, Babin-Boilletot Annie
Pédiatrie Onco-Hématologie, CHRU Hautepierre, Avenue Molière, 67098 Strasbourg Cedex, France.
J Clin Oncol. 2005 Apr 1;23(10):2248-55. doi: 10.1200/JCO.2005.03.119.
Since the recent development of biologic agents targeting oncogenes, increasing attention has been focused on determining the role of tyrosine kinase receptors in the pathogenesis of tumors. Our study was designed to investigate the status of region 4q12, which contains the candidate gene c-kit, and the expression of c-kit by immunohistochemistry (IHC).
Paired blood and biopsy specimens of 68 children treated for high-grade primary osteosarcomas were collected. Microsatellite analysis at two genomic sites containing c-kit gene was performed on paired DNA using a sensible fluorescent polymerase chain reaction technology. To confirm the DNA data, we studied c-kit protein expression by IHC in 56 available paraffin-embedded tumor tissues.
The frequency of allelic imbalance (AI) at locus 4q12 was 39% in the overall population. In agreement with previous studies, we did not detect microsatellite instability, allowing us to hypothesize that this pathway is not implicated. Furthermore, the normal status at locus 4q12 was associated with a significantly better survival in the whole osteosarcoma population (P = .05). IHC overexpression of c-kit was concordant in all cases presenting an AI. However, normal status at locus 4q12 was correlated to an absence of c-kit protein expression in 19 (65.5%) of 29 informative cases.
Allelotyping of locus 4q12, which contains the c-kit gene, could help pediatric osteosarcoma prognostic screening and showed a strong correlation with overexpression of c-kit protein. These results allowed us to hypothesize that, in some cases, a mutation of c-kit gene could lead to a protein overexpression.
自从最近针对癌基因的生物制剂取得进展以来,人们越来越关注确定酪氨酸激酶受体在肿瘤发病机制中的作用。我们的研究旨在调查包含候选基因c-kit的4q12区域的状态,以及通过免疫组织化学(IHC)检测c-kit的表达。
收集了68例接受高级别原发性骨肉瘤治疗的儿童的配对血液和活检标本。使用灵敏的荧光聚合酶链反应技术对配对DNA在两个包含c-kit基因的基因组位点进行微卫星分析。为了证实DNA数据,我们通过免疫组织化学检测了56份可用石蜡包埋肿瘤组织中的c-kit蛋白表达。
在总体人群中,4q12位点的等位基因失衡(AI)频率为39%。与先前的研究一致,我们未检测到微卫星不稳定性,这使我们推测该途径未涉及。此外,在整个骨肉瘤人群中,4q12位点的正常状态与显著更好的生存率相关(P = .05)。在所有呈现AI的病例中,c-kit的免疫组织化学过表达均一致。然而,在29例有信息的病例中,4q12位点的正常状态与19例(65.5%)病例中c-kit蛋白表达缺失相关。
对包含c-kit基因的4q12位点进行等位基因分型有助于小儿骨肉瘤的预后筛查,并显示与c-kit蛋白过表达密切相关。这些结果使我们推测,在某些情况下,c-kit基因突变可能导致蛋白过表达。